HK Stock Market Move | BIOCYTOGEN-B(02315) rose by over 15% in the morning session, and its initial public offering on the Sci-Tech Innovation Board is coming up. The company reached an agreement with Merck at the beginning of the month for antibody authorization cooperation.

BIOCYTOGEN-B (02315) rose more than 15% in early trading, rising 11.41% as of the time of publication, reporting 27.74 Hong Kong dollars, with a turnover of 1202.64 million Hong Kong dollars. On the news front, on September 17, the Shanghai Stock Exchange listing committee announced that the IPO of Bosoma's Sci-Tech Board has reached a critical point, and the initial offering will be reviewed on September 24. In this Sci-Tech Board IPO, Bosoma plans to raise 1.185 billion yuan, with the funds going towards the construction of drug early-stage research service platform projects, antibody drug research and evaluation projects, pre-clinical and clinical research projects, and supplementary working capital. It is worth noting that earlier this month, according to Bosoma's official WeChat account, the company has signed an evaluation agreement with the global leading technology company, Merck, to promote the development of antibody-linked lipid delivery solutions for nucleic acid drugs, such as antibody-linked lipid nanoparticles (LNP). Under the agreement, Bosoma will provide fully human antibodies developed on its own RenMice platform for Merck to evaluate their feasibility for use in antibody-linked LNP formulations. Merck has been granted exclusive rights to acquire selected antibody assets, and Bosoma has the right to receive corresponding fees, sales royalties, and sublicensing royalties.